These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33329553)

  • 1. Redox Regulator
    Chang Y; Li G; Zhai Y; Huang L; Feng Y; Wang D; Zhang W; Hu H
    Front Immunol; 2020; 11():580934. PubMed ID: 33329553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
    Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
    J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-33 induction and signaling are controlled by glutaredoxin-1 in mouse macrophages.
    Weinberg EO; Ferran B; Tsukahara Y; Hatch MMS; Han J; Murdoch CE; Matsui R
    PLoS One; 2019; 14(1):e0210827. PubMed ID: 30682073
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ma W; Zhang K; Bao Z; Jiang T; Zhang Y
    Front Immunol; 2021; 12():659659. PubMed ID: 33936093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches.
    Hu W; Li D; Yang Y; Zheng Y; Zeng J; Sai K
    Int Immunopharmacol; 2024 Sep; 139():112665. PubMed ID: 39002523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFI30 expression is an independent unfavourable prognostic factor in glioma.
    Liu X; Song C; Yang S; Ji Q; Chen F; Li W
    J Cell Mol Med; 2020 Nov; 24(21):12433-12443. PubMed ID: 32969157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
    Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
    CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
    Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
    CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collagen Type III Alpha 1 chain regulated by GATA-Binding Protein 6 affects Type II IFN response and propanoate metabolism in the recurrence of lower grade glioma.
    Huang R; Li Z; Zhu X; Yan P; Song D; Yin H; Hu P; Lin R; Wu S; Meng T; Zhang J; Huang Z
    J Cell Mol Med; 2020 Sep; 24(18):10803-10815. PubMed ID: 32757451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma.
    Wang J; Li X; Wang K; Li K; Gao Y; Xu J; Peng R; Zhang X; Zhang S; Zhou Y; Xu S; Zhang J
    Front Immunol; 2024; 15():1361351. PubMed ID: 38846954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of DOK3 indicates high suppressive immune cell infiltration and unfavorable prognosis of gliomas.
    Liu X; Chen F; Li W
    Int Immunopharmacol; 2020 Jun; 83():106400. PubMed ID: 32193105
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
    Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
    Feng E; Liang T; Wang X; Du J; Tang K; Wang X; Wang F; You G
    J Neuroinflammation; 2019 Feb; 16(1):33. PubMed ID: 30755240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
    Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
    Front Immunol; 2020; 11():603341. PubMed ID: 33363544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.